Assess whether to resubmit, meet, or pause the program (ce6d32)

SITUATION Regulatory-affairs lead in a labeling team facing a boxed-warning debate has one working extract — disproportionate reporting signal workbook — after a CRL citing manufacturing, not efficacy. If disproportionate reporting signal workbook cannot support to resubmit, meet, or, the only defensible Pharma & Life Sciences output is hold.

DECISION Regulatory-affairs lead in a labeling team facing a boxed-warning debate must choose To resubmit, meet, / Pause the program using disproportionate reporting signal workbook after a CRL citing manufacturing, not efficacy.

HYPOTHESES TO TEST 1. Authorize To resubmit, meet, now; disproportionate reporting signal workbook already has the discriminator after a CRL citing manufacturing, not efficacy. 2. Keep Pause the program in force until disproportionate reporting signal workbook is completed after a CRL citing manufacturing, not efficacy for regulatory-affairs lead. 3. Treat disproportionate reporting signal workbook as To resubmit, meet, because both readings appear after a CRL citing manufacturing, not efficacy. 4. Refuse a Pharma & Life Sciences close: regulatory-affairs lead does not have the decision to resubmit, meet, or turns on in disproportionate reporting signal workbook.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in a labeling team facing a boxed-warning debate. 2. Trace CMC, labeling, or pharmacovigilance facts in disproportionate reporting signal workbook after a CRL citing manufacturing, not efficacy. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read disproportionate reporting signal workbook against a CRL citing manufacturing, not efficacy and write the one fact that would move to resubmit, meet, or for regulatory-affairs lead.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (disproportionate reporting signal workbook after a CRL citing manufacturing, not efficacy). The follow-on Clinical and Evidence Strategy action is what regulatory-affairs lead does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to resubmit, meet, or, then the evidence in disproportionate reporting signal workbook, then the action for regulatory-affairs lead - Hypothesis scorecard against disproportionate reporting signal workbook: supported / rejected / untestable - What changes to resubmit, meet, or if a CRL citing manufacturing, not efficacy is later withdrawn - Named option among To resubmit, meet,, Pause the program and the fact that kills the others